BidaskClub lowered shares of Myriad Genetics (NASDAQ:MYGN) from a strong-buy rating to a buy rating in a report published on Wednesday morning.
Other equities analysts have also recently issued reports about the company. ValuEngine raised Myriad Genetics from a hold rating to a buy rating in a report on Friday, November 10th. BTIG Research initiated coverage on Myriad Genetics in a report on Friday, January 5th. They issued a buy rating and a $41.00 target price for the company. Stephens set a $45.00 target price on Myriad Genetics and gave the stock a buy rating in a report on Wednesday, January 3rd. Barclays increased their target price on Myriad Genetics from $30.00 to $35.00 and gave the stock an equal weight rating in a report on Monday, January 22nd. Finally, Zacks Investment Research cut Myriad Genetics from a strong-buy rating to a hold rating in a report on Friday, December 15th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. Myriad Genetics currently has a consensus rating of Hold and an average price target of $31.42.
Myriad Genetics (MYGN) traded down $0.41 during trading on Wednesday, reaching $32.42. The company’s stock had a trading volume of 440,500 shares, compared to its average volume of 713,787. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.81 and a current ratio of 2.05. The firm has a market cap of $2,293.19, a PE ratio of 17.52, a price-to-earnings-growth ratio of 2.31 and a beta of 0.32. Myriad Genetics has a 12-month low of $17.50 and a 12-month high of $41.57.
In related news, Director Walter Phd Gilbert sold 7,500 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $33.19, for a total transaction of $248,925.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Richard M. Marsh sold 37,654 shares of the stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $40.25, for a total value of $1,515,573.50. Following the sale, the vice president now owns 157,648 shares in the company, valued at $6,345,332. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 68,033 shares of company stock worth $2,583,197. 6.70% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MYGN. Xact Kapitalforvaltning AB bought a new position in Myriad Genetics in the 4th quarter valued at $261,000. MetLife Investment Advisors LLC bought a new position in Myriad Genetics in the 4th quarter valued at $1,022,000. BB&T Securities LLC boosted its position in Myriad Genetics by 347.7% in the 4th quarter. BB&T Securities LLC now owns 5,990 shares of the company’s stock valued at $205,000 after buying an additional 4,652 shares during the last quarter. Macquarie Group Ltd. boosted its position in Myriad Genetics by 7.8% in the 4th quarter. Macquarie Group Ltd. now owns 145,500 shares of the company’s stock valued at $4,998,000 after buying an additional 10,500 shares during the last quarter. Finally, Vident Investment Advisory LLC boosted its position in Myriad Genetics by 6.5% in the 4th quarter. Vident Investment Advisory LLC now owns 115,121 shares of the company’s stock valued at $3,954,000 after buying an additional 7,029 shares during the last quarter.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.